Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.2052W HIGH $55.89
Volume
33.01 K
Value Traded
1.06 M
Short % Float
15.11%
+8.4%Week
-19.18%1 Month
-28.23%3 Month
-17.59%6 Month
-97.38%5 Year
-97.93%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
153.88 M
EPS (TTM)
-7.24
P/E Ratio
-
Ent. Value
15.96 M
Total Shares
14.73 M
Float Shares
10.27 M
Insiders
30.28%
Institutions
68.07%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
KRRO Catalyst Timeline
Dated clinical, regulatory and corporate events for Korro Bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Korro Bio, Inc.
268Total events
9Upcoming
49Tier-1 (high impact)
2019 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedKRRO-121Trial
First cohort of healthy volunteers dosed with 2mg/kg KRRO-121 in Phase 1/2 ANCHOR trial
Urea Cycle Disorderssource ↗
●Trial InitiationKRRO-121Trial
Korro initiated Phase 1/2 ANCHOR trial of KRRO-121 in healthy volunteers and UCD patients
Urea Cycle Disorderssource ↗
▲EU Orphan DesignationKRRO-121Ex-US Regulatory
EMA granted Orphan Drug Designation for KRRO-121 for UCDs
urea cycle disorderssource ↗
●Development Candidate NominationKRRO-111Preclinical
Nominated KRRO-111 as development candidate for AATD
Alpha-1 Antitrypsin Deficiencysource ↗
◆Oral PresentationPresentation
Korro to present at 2026 Jefferies Global Healthcare Conference
◆Poster PresentationPresentation
Poster at EASL: Uncontrolled Ammonia is Associated with Increased Healthcare Resource Utilization in Hepatic Encephalopathy
Hepatic Encephalopathysource ↗
◆Oral PresentationPresentation
2026 RBC Capital Markets Global Healthcare Conference Fireside Chat
◆Oral PresentationPresentation
HCW 4th Annual BioConnect Nasdaq Investor Conference Fireside Chat
▲Development Candidate NominationKRRO-111Preclinical
KRRO-111 selected as development candidate for AATD
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
◆Oral PresentationPresentation
Oral presentation at ASGCT: GalNAc-conjugated RNA editing oligonucleotide achieves >90% editing of pathogenic SERPINA1 transcripts, restoring AAT function in AATD models
Alpha-1 Antitrypsin Deficiencysource ↗
◆Oral PresentationKRRO-121Presentation
Oral presentation at ASGCT: KRRO-121 demonstrates robust ammonia clearance in preclinical models
hyperammonemiasource ↗
◆Oral PresentationPresentation
Podium presentation at TIDES USA: Precision RNA editing at scale: platform innovations generating product candidates
◆Poster PresentationPresentation
Poster at ASGCT: Novel triplet chemistries informed by structural biology expand OPERA platform capabilities
◆Poster PresentationPresentation
Poster at ASGCT: RNA Editing of TARDBP reduces TDP-43 aggregation while restoring nuclear localization and splicing function in ALS disease models
ALSsource ↗
◆Oral PresentationPresentation
Preliminary preclinical data from AATD GalNac program to be presented at ASGCT 2026
alpha-1 antitrypsin deficiencysource ↗
●Oral PresentationKRRO-121Presentation
Oral presentation on KRRO-121 at ASGCT 2026
hyperammonemiasource ↗
●Oral PresentationKRRO-111Presentation
Oral presentation on KRRO-111 at ASGCT 2026
Alpha-1 Antitrypsin Deficiencysource ↗
●Poster PresentationPresentation
Poster presentations at ASGCT 2026 featuring OPERA platform and other programs
◆Oral PresentationKRRO-121Presentation
Oral presentation at 3rd International Conference on Ureagenesis Defects and Allied Conditions: KRRO-121 demonstrates robust ammonia clearance in preclinical hyperammonemia models
hyperammonemiasource ↗
◆IND SubmissionKRRO-121IND
Anticipated regulatory filing for first-in-human trial of KRRO-121
hyperammonemia (UCD and HE)source ↗
◆Development Candidate NominationPreclinical
Announce development candidate for GalNAc AATD Program
alpha-1 antitrypsin deficiencysource ↗
▲Runway Guidance UpdateCorporate
Cash runway into second half of 2026 expected to fund KRRO-110 through completion of Phase 1/2a and progress additional candidates
◆Oral PresentationPresentation
Korro to present at TD Cowen 46th Annual Health Care Conference
▼Trial DiscontinuedKRRO-110DiscontinuedTrial
Termination of REWRITE clinical trial for KRRO-110 in AATD
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
◆Development Candidate NominationPreclinical
Development candidate nomination expected for GalNAc-conjugated AATD program
Alpha-1 Antitrypsin Deficiencysource ↗
●R&D DayKRRO-121Presentation
Hosted virtual Analyst Day showcasing KRRO-121
hyperammonemia in urea cycle disorders and hepatic encephalopathysource ↗
▲Preclinical PoCPreclinical
Achieved >90% in vivo RNA editing for GalNAc-conjugated AATD program
alpha-1 antitrypsin deficiencysource ↗
▼Topline ReadoutKRRO-110DiscontinuedClinical Data
KRRO-110 produced functional M-AAT protein but did not reach projected levels in AATD patients
Alpha-1 Antitrypsin Deficiencysource ↗
▲Development Candidate NominationKRRO-121Preclinical
Nominated KRRO-121 for hyperammonemia
hyperammonemiasource ↗
▼Partnership / LicenseCorporate
Novo Nordisk collaboration paused for 12 months beginning November 2025
▼Program DiscontinuationKRRO-110DiscontinuedCorporate
Announced KRRO-110 discontinuation and workforce reductions in November 2025
◆Interim AnalysisKRRO-110DiscontinuedTrial
Interim Phase 1/2 clinical trial readout for KRRO-110 in ZZ AATD patients anticipated in H2 2025
alpha-1 antitrypsin deficiency (AATD)source ↗
▲Enrollment MilestoneKRRO-110DiscontinuedTrial
Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple SAD cohorts
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
▲EU Orphan DesignationKRRO-110DiscontinuedEx-US Regulatory
EMA granted Orphan Drug Designation to KRRO-110 for AATD
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
Past FDA Catalysts and PDUFA Decisions
How KRRO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-14 | KRRO-121 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D21 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 93%
Micro Cap(rank 612 of 658)
Percentile Rank
Korro Bio, Inc. faces pipeline headwinds (21/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KRRO-121 Small moleculeNCT07773246 | Urea Cycle Disorders, Inborn | Phase 1 | RECRUITING | 30 | Sep 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every KRRO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| FX-322 | Presbycusis (Age-Related Hearing Loss) | Phase 1b | 2021-05-13 | no significant treatment effect with FX-322 administration compared to placeboRead More | Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results Data From Recent FX-322 Clinical Readouts, Including New Data from Phase 1b Study in Presbycusis (Age-Related Hearing LossRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Atlas Venture Fund XI, L.P.Shareholder | Sell | 31,888 | $13.81 | 09/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KRRO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| NEA Management Company, LLC | 1.1 % (37.5 %) | 17.11 M | 1.30 M |
KRRO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KRRO ranks across every disease it competes in
Competitive Position is a premium feature
See how KRRO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKRRO News
KRRO▼ -1.2%today
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
Korro Bio has initiated a Phase 1/2 clinical trial for KRRO-121, targeting hyperammonemia in patients with urea cycle disorders (UCDs). The first cohort of healthy volunteers has been dosed, with plans to begin dosing UCD patients in 2027. The trial aims to assess safety, tolerability, and pharmacokinetics of KRRO-121, which has shown promise in preclinical studies.
Read more →KRROKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Bio has granted non-statutory stock options to three new employees as part of its 2026 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The options, totaling 5,000 shares at an exercise price of $12.93, vest over four years. This move reflects Korro's commitment to attracting talent while advancing its OPERA platform for genetic medicine development.
Read more →KRROKorro to Participate in Upcoming Investor Conferences
Korro, a biopharmaceutical company, announced its participation in two upcoming investor conferences, including the Citi 2026 Biopharma Back to School Summit and the 2026 Cantor Global Healthcare Conference. CEO Ram Aiyar will engage in fireside chats at both events, highlighting Korro's innovative OPERA platform for RNA editing. This platform aims to develop genetic medicines for various diseases.
Read more →KRRO▲ +5.4%on this news· ran to +16% by day 3
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Korro Bio reported its second quarter 2026 financial results, highlighting progress in its RNA editing programs. The company is set to begin first-in-human trials for KRRO-121, which has received Orphan Drug Designation from the EMA. Additionally, KRRO-111 has been nominated as a development candidate for Alpha-1 Antitrypsin Deficiency, showing promising preclinical data. Despite a net loss, Korro's financial position remains strong with sufficient cash to support its initiatives.
Read more →KRRO▼ -7.3%on this news
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Korro Bio, Inc. has announced the grant of non-statutory stock options to seven newly hired employees as part of its 2026 Inducement Plan. The options, which have varying exercise prices and vesting schedules, were approved by the company's Compensation Committee. This move is aligned with Nasdaq Listing Rule 5635(c)(4) and reflects Korro's commitment to attracting talent in the biopharmaceutical sector.
Read more →KRRO▲ +11.6%on this news
Korro to Present at the 2026 Jefferies Global Healthcare Conference
Korro Bio, Inc. announced that its CEO, Dr. Ram Aiyar, will present at the 2026 Jefferies Global Healthcare Conference in New York. The presentation is scheduled for June 4, 2026. Korro is focused on developing genetic medicines using its OPERA platform, which enables precise RNA editing for therapeutic applications.
Read more →KRRO▼ -8.2%on this news
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Korro Bio has selected KRRO-111 as a development candidate for treating Alpha-1 Antitrypsin Deficiency (AATD). This GalNAc-conjugated oligonucleotide has shown promising preclinical results, achieving over 90% editing of the SERPINA1 transcript and significant reduction of pathogenic Z-protein. The company aims to advance KRRO-111 into clinical trials, highlighting its potential as a best-in-class therapy.
Read more →KRROKorro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro Bio reported its first quarter 2026 financial results, highlighting significant advancements in its RNA editing platform. The company is on track for a regulatory filing of its lead program, KRRO-121, aimed at treating hyperammonemia in patients with urea cycle disorders. Additionally, Korro achieved over 90% in vivo RNA editing in its GalNac-conjugated program for alpha-1 antitrypsin deficiency, supported by an $85 million private placement to fund ongoing research.
Read more →KRRO▲ +6%on this newsshared move
Korro to Participate in Upcoming May 2026 Investor Conferences
Korro, a biopharmaceutical company, announced its participation in two upcoming investor conferences in May 2026. The events will feature key executives discussing the company's innovative OPERA platform, which is designed for developing genetic medicines. This platform aims to provide precise RNA editing for therapeutic applications, enhancing the potential for effective treatments.
Read more →KRROKorro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
Korro Bio, Inc. will present its RNA editing technology at several upcoming scientific conferences, including ASGCT and EASL. Key presentations will focus on the efficacy of their oligonucleotide delivery system and its potential applications in treating hyperammonemia and Alpha-1 Antitrypsin deficiency. The company aims to leverage its innovative platform to advance genetic medicines.
Read more →KRRO▲ +11.3%on this news
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Korro Bio, Inc. reported its financial results for Q4 and full year 2025, highlighting a cash position of $85.2 million and increased collaboration revenue. However, the company faced a net loss of $117.3 million, largely due to impairment charges. Korro aims to leverage its RNA editing platform for future growth and has secured funding through a recent private placement.
Read more →KRRO▲ +10%on this news
Korro Announces Oversubscribed $85 Million Private Placement
Korro Bio, Inc. announced an oversubscribed $85 million private placement led by Venrock Healthcare Capital Partners. The funds will support the company's RNA editing programs, including clinical data for KRRO-121 and a GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency. The financing is expected to extend Korro's cash runway into 2028.
Read more →KRROKorro to Present at the TD Cowen 46th Annual Health Care Conference
Korro Bio, Inc. will present at the TD Cowen 46th Annual Health Care Conference in Boston from March 2-4, 2026. CEO Ram Aiyar is scheduled to speak on March 3 at 11:10 a.m. ET. The company focuses on RNA editing for genetic medicines aimed at treating rare and prevalent diseases.
Read more →KRROForward-Looking Statements and Disclaimers Forward-Looking Statements Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Securities Litigat
Korro Bio, Inc. (ticker: KRRO) is advancing KRRO-121, a potential first-in-class treatment aimed at addressing ammonia control in patients with urea cycle disorders. The company anticipates filing for regulatory approval in the second half of 2026, highlighting KRRO-121's innovative approach through RNA editing to enhance the function of glutamine synthetase. This treatment could significantly benefit patients struggling with high ammonia levels due to conditions like hepatic encephalopathy. However, the development is subject to typical biopharmaceutical risks, including the uncertainties surrounding clinical trial outcomes and regulatory approval processes.
Read more →KRROKorro to Host Virtual Analyst Day on January 27, 2026
Korro Bio, Inc. announced a virtual Analyst Day scheduled for January 27, 2026, featuring discussions on KRRO-121, aimed at treating hyperammonemia. The event will include insights from company management, a clinical hepatologist, and a caregiver, highlighting the unmet needs in ammonia-driven diseases. Korro plans to file for regulatory approval for KRRO-121 in the second half of 2026.
Read more →KRROCONCEPT PROGRAM / INDICATION DELIVERY DISCOVERY PRECLINICAL DEVELOPMENT PHASE 1 PHASE 2 PHASE 3 Stabilize Protein KRRO-121 Hyperammonemia GalNAc (SC) Repair Pathogenic Variant AATD GalNAc (SC) Allosteric Activator Longev
Korro Bio, Inc. (KRRO) has provided an update on its pipeline and future development plans, emphasizing its approach to RNA editing and drug delivery targeting AATD and hyperammonemia. Despite highlighting promising programs, the company faces uncertainties associated with biopharmaceutical development, including regulatory approvals and clinical trial outcomes. The forward-looking statements suggest caution as Korro navigates these risks, compounded by the recent termination of its clinical trial for KRRO-110. The organization aims to make significant progress with its TDP43 pipeline in the coming years.
Read more →About Korro Bio, Inc.
Headquarters60 FIRST STREET, CAMBRIDGE, MA, 02141
BIOPHARMAWATCH ELITE PLUS
Trade the next KRRO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime